- Home
- CCEL vs CTSO Comparison
CCEL vs CTSO Comparison
Compare CCEL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- CTSO
- Stock Information
- Founded
- CCEL 1989
- CTSO 1997
- Country
- CCEL United States
- CTSO United States
- Employees
- CCEL N/A
- CTSO N/A
- Industry
- CCEL Managed Health Care
- CTSO Medical/Dental Instruments
- Sector
- CCEL Health Care
- CTSO Health Care
- Exchange
- CCEL Nasdaq
- CTSO Nasdaq
- Market Cap
- CCEL 50.0M
- CTSO 48.2M
- IPO Year
- CCEL 1997
- CTSO N/A
- Fundamental
- Price
- CCEL $7.80
- CTSO $0.87
- Analyst Decision
- CCEL
- CTSO Strong Buy
- Analyst Count
- CCEL 0
- CTSO 3
- Target Price
- CCEL N/A
- CTSO $4.67
- AVG Volume (30 Days)
- CCEL 13.9K
- CTSO 135.6K
- Earning Date
- CCEL 12-24-2024
- CTSO 11-07-2024
- Dividend Yield
- CCEL 3.14%
- CTSO N/A
- EPS Growth
- CCEL N/A
- CTSO N/A
- EPS
- CCEL N/A
- CTSO N/A
- Revenue
- CCEL $31,838,476.00
- CTSO $37,739,531.00
- Revenue This Year
- CCEL $3.97
- CTSO $8.08
- Revenue Next Year
- CCEL $0.91
- CTSO $12.80
- P/E Ratio
- CCEL N/A
- CTSO N/A
- Revenue Growth
- CCEL 1.95
- CTSO 1.80
- 52 Week Low
- CCEL $4.47
- CTSO $0.70
- 52 Week High
- CCEL $9.50
- CTSO $1.97
- Technical
- Relative Strength Index (RSI)
- CCEL 45.13
- CTSO 42.77
- Support Level
- CCEL $7.60
- CTSO $0.80
- Resistance Level
- CCEL $9.10
- CTSO $1.09
- Average True Range (ATR)
- CCEL 0.27
- CTSO 0.08
- MACD
- CCEL -0.15
- CTSO -0.00
- Stochastic Oscillator
- CCEL 23.61
- CTSO 13.19
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.